Cancer therapy disparity: Unequal access to breast cancer therapeutics and drug funding in Canada

Current Oncology

Volumn 14, Issue , 2007, Pages S3-S10

  Verma, S ^a   Sehdev, S ^b   Joy, A A ^c  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b William Osler Health Centre   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58649084292     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.153     Document Type: Article

References (37)

1. Benedict A, Brown RE. Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer. Expert Opin Pharmacother 2005;6:1789–801.
2. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Toronto: Canadian Cancer Society; 2007.
3. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Hormone Res 1962;18:387–414.
4. Dickson RB, Lippman ME. Molecular basis of breast cancer. In: Mendelsohn J, Howley PH, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia: W.B. Saunders; 1995: 358–86.
5. Westwell AD. New aromatase inhibitors with potential in breast cancer treatment. Drug Discovery Today 2006;11:1041.
6. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s–70s.
7. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351:1451–67.
8. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007;72:7–25.
9. Brodie AM. Aromatase inhibitors in the treatment of breast cancer. J Steroid Biochem Mol Biol 1994;49:281–7.
10. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342–55.
11. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993;77:1622–8.
12. Brueggemeier RW. Update on the use of aromatase inhibitors in breast cancer. Expert Opin Pharmacother 2006;7:1919–30.
13. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005;23:619–29.
14. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569–83.
15. National Institute for Health and Clinical Excellence (NICE). Hormonal therapies for the adjuvant treatment of early oestrogen receptor positive breast cancer. London, U.K.: NICE; 2006.
16. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–2.
17. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 2002; 359:2131–9.
18. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or on Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802–10.
19. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353: 2747–57.
20. Eisen A, Trudeau M, Shelley W, Sinclair S, and the Breast Cancer Disease Site Group. The Role of Aromatase Inhibitors in Adjuvant Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: A Clinical Practice Guideline. Toronto: Cancer Care Ontario; October 25, 2005.
21. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25: 486–92.
22. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.
23. Coombes RC, Paridaens R, Jassem J, et al. First mature analysis of the Intergroup Exemestane Study (IES): A randomized trial in postmenopausal patients with early breast cancer who remained disease-free after two to three years of tamoxifen [abstract LBA527]. Proc Am Soc Clin Oncol 2006;24:18S.
24. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366: 455–62.
25. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138–47.
26. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): A randomized controlled trial. Lancet 2007;369:559–70. [Erratum in: Lancet 2007;369:906]
27. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer [abstract 847]. J Clin Oncol 2004;22:847.
28. Goss P. Update on the MA.17 extended adjuvant trial. Best Pract Res Clin Endocrinol Metab 2006;20(suppl 1):S5–13.
29. Andreeta C, Smith I. Adjuvant endocrine therapy for early breast cancer. Cancer Lett 2007;251:17–27.
30. Jonat W., Hilpert F, Kaufmann M. Aromatase inhibitors: A safety comparison. Expert Opin Drug Saf 2007;6:165–74.
31. Verma S, Pritchard K, Blais N, Gelmon K. Canadian clinical practice patterns survey of adjuvant therapies for breast cancer [abstract 2106]. Breast Cancer Res Treat 2006;100(suppl 1):S5.
32. Canada, Office of the Prime Minister. Home page > Media centre > Prime Minister announces Canadian Partnership Against Cancer [Web page]. Montreal: November 24, 2006. [Available online at: Www.pm.gc.ca/eng/media.asp?category=1&id=1417; cited July 2007]
33. Saskatchewan Cancer Agency. Follow-Up Guidelines: Breast Cancer. Regina, SK: Saskatchewan Cancer Agency; 2005. [Available online at: Www.saskcancer.ca/adx/aspx/adxGetMedia.aspx?DocID=93, 3,1,Documents&MediaID=36&Filename=PSA701+AA+-+Follow-up+Guidelines+-+Breast+Cancer+-+V1.0.pdf; cited January 2007]
34. Khoo K, Ragaz J, Hryniuk W, Gowing J, Savage C. Cancer drug access in Canada. Part 2. One year later: Are we making progress? In: Hryniuk W, Eaton G, Gowing J, et al., eds. Cancer Advocacy Coalition of Canada (CACC) Report Card on Cancer in Canada. Vol. 9. Winter 2006–07. Toronto: CACC; 2006. [Available online at: Www.canceradvocacy.ca/reportcard/2006/report.card.2006.pdf; cited January 2007]
35. Cancer Care Manitoba. Home page > Doctors & Health Professionals > CCMB Cancer Management Guidelines [Web resource]. Winnipeg: Cancer Care Manitoba; n.d. [Available at: Www.cancercare.mb.ca/professionals/cancer_mgmt_guidelines.shtml; cited January 2007]
36. BC Cancer Agency. Home page > Health Professionals Info > Cancer Management Guidelines > Breast > 6. Management > Policy on Defined Use of Up-Front Aromatase Inhibitor Therapy for Adjuvant Hormonal Management of High Risk ER+ Breast Cancer [Web resource]. Vancouver: BC Cancer Agency; October 2006. [Available at: Www.bccancer.bc.ca/NR/exeres/C3667614-C976-41CC-809B-3F5ADCEBB038.htm; cited January 2007]
37. Ontario, Ministry of Health and Long-Term Care. Home page > Public Information > Transparent Drug System for Patients Act, 2006 [Web resource]. Toronto: Queen’s Printer for Ontario; n.d. [Available at: Www.health.gov.on.ca/english/public/legislation/drugs/hu_drugsact.html; cited January 2007]